Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 18 new employees on April 23, 2026, under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 18 new employees on April 23, 2026, under Nasdaq Listing Rule 5635(c)(4).

The awards include non‑statutory stock options to purchase an aggregate of 320,900 shares at the closing price on April 21, 2026, and restricted stock units for an aggregate of 102,100 shares. Options have a 10‑year term; options vest over four years (25% after one year, then quarterly) and RSUs vest in four equal annual installments, all subject to continued service and the 2024 Inducement Stock Incentive Plan.

Positive

• Grants support hiring of 18 new employees
• Awards use standard four‑year vesting to align incentives

Negative

• Potential dilution of up to 423,000 shares from options and RSUs

Argus Apr 24 session

-3.39% close to close Open Argus

Details

News Market Reaction – DYN

In the Apr 24 session, DYN declined 3.39%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement equity awards to 18 new employees, totaling 320,900 sto...

Analysis

This announcement details routine inducement equity awards to 18 new employees, totaling 320,900 stock options and 102,100 RSUs under Dyne’s 2024 Inducement Stock Incentive Plan. The options have a 10-year term with four-year vesting, aligning employee incentives with long-term performance. In context, Dyne recently reported $1.1 billion in cash and runway into Q1 2028, plus multiple positive clinical and regulatory milestones, so this filing mainly refines the picture around compensation and ownership dynamics.

Key Figures

Current price: $19.67 New employees: 18 employees Stock options granted: 320,900 options +5 more

Current price

$19.67

Pre-news close on April 23, 2026

New employees

18 employees

Recipients of inducement equity awards

Stock options granted

320,900 options

Aggregate non-statutory options under inducement awards

RSUs granted

102,100 shares

Aggregate restricted stock units under inducement awards

Option term

10 years

Term of inducement stock options

Vesting period

4 years

Vesting schedule for options and RSUs, service-based

Year-end cash

$1.1 billion

Cash balance at end of 2025 (reported Mar 2, 2026)

Runway guidance

Into Q1 2028

Capital runway reaffirmed in Q4/FY25 results

Historical Context

5 past events · Latest: Apr 01

5 events

1. Apr 01

   Conference participation

   24h Move

   -0.2%

   Planned AMCP presentations and payer-focused activities for DMD and DM1.

2. Mar 08

   Phase 3 initiation

   24h Move

   +19.0%

   Start of Phase 3 HARMONIA trial of z-basivarsen in DM1.

3. Mar 08

   Clinical data update

   24h Move

   +19.0%

   New positive 24‑month cardiopulmonary results from DELIVER trial in DMD.

4. Mar 02

   Earnings and pipeline

   24h Move

   +3.4%

   Q4/FY25 results, positive REC topline and strong cash runway.

5. Feb 25

   Investor conferences

   24h Move

   +3.5%

   Management participation in multiple March investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-statutory stock options, restricted stock units, inducement stock incentive plan

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statutory stock options financial

"consisted of non-statutory stock options to purchase up to an aggregate"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units financial

"and restricted stock units with respect to an aggregate of 102,100 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement stock incentive plan financial

"subject to the terms and conditions of ... Dyne’s 2024 Inducement Stock Incentive Plan."

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 18 new employees. The awards were made as an inducement material to the new employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 320,900 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on April 21, 2026, and restricted stock units with respect to an aggregate of 102,100 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938

FAQ

What inducement equity did Dyne Therapeutics (DYN) grant on April 23, 2026?

Dyne granted inducement awards to 18 hires consisting of 320,900 stock options and 102,100 restricted stock units. According to the company, awards were made under Nasdaq Listing Rule 5635(c)(4).

At what price were the Dyne (DYN) stock options set for the April 2026 inducement grants?

The options’ exercise price equals the closing price on April 21, 2026. According to the company, the exercise price matches that Nasdaq closing price on that date.

What are the vesting terms for Dyne Therapeutics’ (DYN) April 2026 inducement awards?

Options vest over four years with 25% after one year, then quarterly vesting; RSUs vest in four equal annual installments. According to the company, vesting is subject to continued service.

How long is the term on the inducement stock options granted by Dyne (DYN)?

The inducement stock options carry a 10‑year term from grant. According to the company, the options expire ten years after grant subject to award agreement terms.

Do Dyne’s April 2026 inducement awards affect shareholder dilution and by how much?

The awards could dilute existing shareholders by up to 423,000 shares if fully issued and exercised. According to the company, aggregate awards equal 320,900 options plus 102,100 RSUs.